Tourmaline Bio News

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients

GlobeNewswireMay 23 19:10

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial

– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of

GlobeNewswireMay 16 19:00

Buy Rating Affirmed for Tourmaline Bio Amid Progress in TOUR006 Trials and Expansion Opportunities

TipRanksMay 16 16:07

Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)

TipRanksMay 14 22:05

HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio with a Buy and maintains $48 price target.

Analyst UpgradesMay 14 21:57

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)

TipRanksMay 14 21:50

Tourmaline Bio | 10-Q: Quarterly report

SEC announcementMay 14 04:20 · Announcements

Tourmaline Bio Ended The First Quarter With $350.3M Of Cash, Cash Equivalents And Investments, Providing Cash Runway Into 2027

Tourmaline Bio Ended The First Quarter With $350.3M Of Cash, Cash Equivalents And Investments, Providing Cash Runway Into 2027

BenzingaMay 13 19:19

Tourmaline Bio Q1 2024 GAAP EPS $(0.55) Beats $(0.66) Estimate

Tourmaline Bio Q1 2024 GAAP EPS $(0.55) Beats $(0.66) Estimate

BenzingaMay 13 19:18

Tourmaline Bio 1Q Loss/Shr 55c >TRML

Tourmaline Bio 1Q Loss/Shr 55c >TRML

Dow JonesMay 13 19:04

Press Release: Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Dru

Dow JonesMay 13 19:00

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 23:34

Tourmaline Bio Price Target Maintained With a $74.00/Share by Truist Securities

Tourmaline Bio Price Target Maintained With a $74.00/Share by Truist Securities

Dow JonesMar 26 00:37

Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

TipRanksMar 25 20:25

PHIO and MGRM Among Healthcare Movers

Seeking AlphaMar 21 22:12

Dow Jumps 200 Points; US Weekly Jobless Claims Fall

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ ros

BenzingaMar 21 21:47

Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected

US stocks look set to open higher in Thursday's trading session as investors parse jobless and manufacturing data released earlier this morning and look ahead to home sales data set for release later

MT NewswiresMar 21 21:22

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV

BenzingaMar 21 21:05

BILI, EXAI and ENVB Among Pre-market Losers

Seeking AlphaMar 21 20:43

Tourmaline Bio Price Target Raised to $72.00/Share From $41.00 by Jefferies

Tourmaline Bio Price Target Raised to $72.00/Share From $41.00 by Jefferies

Dow JonesMar 21 20:22